Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Glen Allen, Virginia. Show more

Location: 4870 Sadler Road, Glen Allen, VA, 23060, United States | Website: https://www.adial.com | Industry: Biotechnology | Sector: Healthcare

Market Cap

8.164M

52 Wk Range

$0.22 - $1.30

Previous Close

$0.37

Open

$0.36

Volume

629,111

Day Range

$0.34 - $0.37

Enterprise Value

2.231M

Cash

5.915M

Avg Qtr Burn

-1.621M

Insider Ownership

2.47%

Institutional Own.

2.62%

Qtr Updated

06/30/25

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
AD04 Details Alcohol use disorder	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ADO-5030 Details Asthma	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.